1504 Primary analysis of the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE trial of RP1 plus nivolumab, including clinical subgroup and initial biomarker data

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Medicine

Cancer Oncology

Internal Medicine

Molecular Biology

Nivolumab

Show all topics

DOI

10.1136/jitc-2024-sitc2024.1504

License

CC-BY-NC

Other Formats

PDF